Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 study of GB001

Next Previous
Trial Profile

A Phase 3 study of GB001

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 001 (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 15 May 2020 New trial record
  • 12 May 2020 According to an Gossamer Bio media release, based on the results of the interim analysis of the LEDA study and the IDMC recommendation, the company has commenced initial Phase 3 planning and supportive activities in anticipation of the completion of the LEDA study and final analysis of the study data. The final decision to proceed to Phase 3 will be made based on the totality of the final data from LEDA study, as well as discussions with global regulatory authorities.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top